Erratum: Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment (AIDS Research And Human Retroviruses (2013) 29:5 DOI: 10.1089/aid.2012.0301));Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment

AIDS Research and Human Retroviruses

Volumn 29, Issue 5, 2013, Pages 746-754

  Shibata, Annemarie ^a   McMullen, Emily ^a   Pham, Alex ^a   Belshan, Michael ^a   Sanford, Bridget ^a   Zhou, You ^a   Goede, Michael ^b   Date, Abjijit A ^b   Destache, Christopher J ^b  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; POLYGLACTIN; RHODAMINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL FRACTIONATION; CELL MEMBRANE; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSKELETON; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IMMUNOCOMPETENT CELL; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; SURFACE CHARGE; SUSTAINED DRUG RELEASE; VIRUS REPLICATION;

EID: 84876909626     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0301.cnx     Document Type: Erratum

References (41)

1. UNAIDS: AIDS epidemic update World Health Organization 2009, 30.
2. Barouch DH, Liu J, Li H, Maxfield LF, Lynch DM, Lampietro MJ, SanMiguel A, Seaman MS, Ferrari G, Forthal D, Ourmanov I, Hirsch VM, Carville A, Mansfield KG, Stablein D, Pau MG, Schuitemaker H, Sadoff JC, Billings EA, Rao M, Robb ML, Kim JH, Marovich MA, Goudsmit J, and Michael NL: Vaccine protection against acquisition of neutralizationresistant SIV challenges in rhesus monkeys. Nature 2012;482:89-93.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D and the CAPRISA 004 Trial Group: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide for the prevention of HIV infection in women. Science 2010;329:1168-1174.
4. Grant RM, Lama JR, Anderson PL, McMahan V, Lui AY, Vargas L, Goicochea P, Gasapia M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernandez T, Veloso VG, Buchbinder SP, Chariyalertsak S, SchechterM, Bekker LG, Mayer KH, Kallas EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV, and the iPrEx Study Team: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
5. Chun TW, NIckle DC, Justement JS, Meyers JH, Roby G, Hallahan CW, Kottilil S, Moir S, Mican JM, Mullins JI, Ward DJ, Kovacs JA, Mannon PJ, and Fauci AS: Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008;197:714-720. (Pubitemid 351364472)
6. Clements JE, Babas T, Mankowski JL, Suryanarayana K, Piatak M Jr, Tarwater PM, Lifson JD, and Zink MC: The central nervous system as a reservoir for simian immunodeficiency virus (SIV): Steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis 2002;186:905-913.
7. Gunthard HF, Havlir DV, Fiscus S, Zhang AQ, Eron J, Mellors J, Gulick R, Frost SD, Brown AJ, Schleif W, Valentine F, Jonas L, Meibohm A, Ignacio CC, Isaacs R, Gamagami R, Emini E, Haase A, Richman DD, and Wong JK: Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001;183:1318-1327. (Pubitemid 32337113)
8. Yeh RF, Renk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvahis M, Horton Al, Fiscus SA, and Patterson KB: Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type1-infected women. Antimicrob Agents Chemother 2009;53:2367-2374.
9. Kay MS: Silent, but deadly-eliminating reservoirs of latent HIV. Trends Biotechnol 2003;2:420-423. (Pubitemid 38366060)
10. Destache CJ, Belgum T, Goede M, Shibata A, and Belshan MA: Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother 2010; 65:2183-2187.
11. Mann DL, O'Brien SJ, Gilbert DA, Reid Y Popovic M, Read-Connole E, Gallo RC, and Gazdar AF: Origin of the HIVsusceptible human CD4 + cell line H9. AIDS Res Hum Retroviruses 1989;5:253-255.
12. Sundstrom C and Nilsson K: Establishment and characterization of a human histiocytic lymphoma cell line (U937) Int J Cancer 1976;17:565-577.
13. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, and Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986;47:333-348. (Pubitemid 17210148)
14. Destache CJ, Belgum R, Christensen K, Shibata A, Sharma A, and Dash AK: Combination antiretroviral drugs in PLGA nanoparticles for HIV-1. BMC Infect Dis 2009;9:198.
15. Lee WK, Park JY, Yang EH, Suh H, Kim SH, Chung DS, Choi K, Yang CW, and Park JS: Investigation of the factors influencing the release rates of cyclosporin A-loaded microand nanoparticles prepared by high-pressure homogenizer. J Control Release 2000;84(3):115-123. (Pubitemid 35435316)
16. Mehta AK, Yadav KS, and Sawant KK: Nimodipine loaded PLGA nanoparticles: Formulation optimization using factorial design, characterization and in vitro evaluation. Curr Drug Deliv 2007;4(3):185-193. (Pubitemid 47025402)
17. Dong Y and Feng SS: Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. Int J Pharm 2007;342(1-2):208-814.
18. Couvreur P, Kante B, Crislain L, Roland M, and Speiser P: Toxicity of polyalkcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. J Pharm Sci 1982;71:790-792.
19. Beck P, Kreuter J, Reszka R, and Richtner I: Influence of polybutylcyanacrylate nanoparticles and liposomes on the efficacy and toxicity of anticancer drug mitoxantrone in murine tumour models. J Microencapsul 1993;10:101-114. (Pubitemid 23069818)
20. Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, and Millis KH: Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: Effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 2001;19:1940-1950. (Pubitemid 32178342)
21. Shenoy D, Little S, Langer R, and Amiji M: Poly(ethylene oxide)-modified poly(b-amino) ester nanoparticles as a pHsensitive system for tumor-targeted delivery of hydrophobic drugs: Part 2. In vivo distribution and tumor localization studies. Pharm Res 2005;22:2107-2114. (Pubitemid 41821590)
22. Mahapatro A and Singh DK: Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol 2011;9:55.
23. Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, Sanchez de la Rosa R, Giralt M, Alvarez ML, Lopez-Dupla M, Torres F, Villarroya F, Cihlar T, and Domingo P: In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 2006;50:3824-3832. (Pubitemid 44684899)
24. Groener JB, Seybold U, Vollbrecht T, and Bogner JR: Decrease in mitochondrial transmembrane potential in peripheral blood mononuclear cells of HIV-uninfected subjects undergoing HIV postexposure prophylaxis. AIDS Res Hum Retroviruses 2011;27:969-972.
25. Speck RR, Yu X-F, Hildreth J, and Flexner C: Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis 2002;186(3):332-340. (Pubitemid 34816316)
26. Peroni RN, Di Gennaro SS, Hocht C, Chiappetta DA, Rubio MC, Sosnik A, and Bramuglia GF: Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat. Biochem Pharmcol 2011;82(9):1227-1233.
27. Panyam J, Zhou WZ, Prabha S, Sahoo SK, and Labhasetwar V: Rapid endo-lysosomal escape of poly(DL-lactide-coglycolide) nanoparticles: Implications for drug and gene delivery. FASEB J 2002;16(10):1217-1226. (Pubitemid 34815409)
28. Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, Fischl MA, Long MC, Kuritzkes DR, and Sommadossi JP: Intracellular nucleoside triphosphate concentrations in HIVinfected patients on duel nucleoside reverse transcriptase inhibitor therapy. Antivir Ther 2007;12(6):981-986. (Pubitemid 47492569)
29. Fletcher CV, Kawie SP, Kakuda TN, Anderson PL, Bushman LR, Brundage RC, and Remmel RP: Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS 2000;14(14):2137-2144.
30. Anderson PL, Kakuda TN, Kawle S, and Fletcher CV: Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003;17(15):2159-2168. (Pubitemid 37338889)
31. Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, and Henry K: Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 16(4):551-560. (Pubitemid 34218850)
32. Aweeka FT, Kang M, Yu JY, Lizak P, Alston B, Chung RT, and the AIDS Clinical Trials Group 5092s Study Team: Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. HIV Med 2007;8(5):288-294. (Pubitemid 46901527)
33. Lamotte C, Landman R, Peytavin G, Mentre F, Gerbe J, Brun-Vezinet F, Boue F, Spiridon G, Valantin MA, Michelet C, Farinotti R, and Yeno P: Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-infected patients. (IMEA015 Study) Antivir Ther 2004;9(2):247-256. (Pubitemid 38560217)
34. Chaillou S, Durant J, Garraffo R, Georgenthum E, Roptin C, Levenbergh P, Dunais B, Bondain V, Roger PM, and Dellamonica P: Intracellular concentration of protease inhibitors in HIV-1-infected patients: Correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin Trial 2002;3(6):493-501. (Pubitemid 36013558)
35. Anderson PL, Brundage RC, Kakuda TN, and Fletcher CV: CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. Clin Pharmacol Ther 2002;71:280-285. (Pubitemid 34311457)
36. Cohen J: Tissue says blood is misleading, confusing HIV cure efforts. Science 2011;334(6063):1614.
37. Riddler SA, Haubrich R, DiRenzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, and the AIDS Clinical Trials Groups Study A5142 Team: Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008 358:2095-2106. (Pubitemid 351679596)
38. Calmy A, Petoumenos K, Lewden C, Law M, Bocquentin F, Hesse K, Cooper D, Carr A, Bonnet F, Aquitaine Cohort, Australian HIV Observational Database, and St Vincent's Hospital Cohort Study Groups: Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: Experience from 334 patients in three cohorts. HIV Med 2007;8:171-180. (Pubitemid 46915688)
39. Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, and Piot PK: Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: A multinational study. PLoS One 2012;7:e282380.
40. Farmer P, Leandre F, Mukherjee J, Gupta R, Tarter L, and Kim JY: Community-based treatment of advanced HIV disease: Introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Org 2001;79:1145-1151. (Pubitemid 34084008)
41. Bangsberg DR, Ragland K, Monk A, and Deeks SGA: Single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV + homeless and marginally housed people. AIDS 2010;24:2835-2840.